References
- Li Wan Po A, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997; 315:1565–1571.
- Wetli CV, Bednarczyk LR. Deaths related to propoxyphene overdose: a ten year assessment. South Med J 1980; 73:1205–1209.
- Hantson P, Evenepoel M, Ziade D, Hassoun A, Mahieu P. Adverse cardiac manifestations following dextropropoxyphene overdose: can naloxone be helpful?. Ann Emerg Med 1995; 25:263–266.
- Bateman DN, Sandilands EA. European Medicines Evaluation Agency bans dextropropoxyphene: a landmark decision for clinical toxicology?. Clin Toxicol 2009; 47:782–783.
- Sandilands EA, Bateman DN. Co-proxamol withdrawal has reduced suicide from drugs in Scotland. Br J Clin Pharmacol 2008; 66:290–293.
- Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, Smith KL, Kapur N, Gunnell D. Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis. BMJ 2009; 338:b2270.
- Food and Drug Administration. FDA Takes Actions on Darvon, Other Pain Medications Containing Propoxyphene. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170769.htm 8 July 2009].
- Bronstein AC, Spyker DA, Cantilena LRJr, Green JL, Rumack BH, Heard SE. 2007 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 25th annual report. Clin Toxicol 2008; 46:927–1057.
- American Association of Poison Control Centers’ Annual Data Reports. http://www.aapcc.org/dnn/NPDS/AnnualReports/tabid/125/Default.aspx 8 July 2009.